Health Catalyst, Inc. (NASDAQ:HCAT) Shares Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc raised its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 7.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,750,000 shares of the company’s stock after buying an additional 195,525 shares during the period. Impax Asset Management Group plc owned about 4.52% of Health Catalyst worth $19,442,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in HCAT. Primecap Management Co. CA lifted its holdings in shares of Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after acquiring an additional 25,000 shares during the last quarter. Geode Capital Management LLC raised its position in Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after acquiring an additional 66,896 shares in the last quarter. State Street Corp grew its position in Health Catalyst by 2.5% during the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after buying an additional 28,251 shares during the period. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst during the 3rd quarter valued at approximately $6,858,000. Finally, Portolan Capital Management LLC purchased a new position in Health Catalyst in the 3rd quarter valued at approximately $5,402,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $5.01 on Tuesday. The company’s fifty day simple moving average is $6.19 and its 200-day simple moving average is $7.29. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 52 week low of $4.96 and a 52 week high of $9.24. The company has a market cap of $304.85 million, a PE ratio of -3.71 and a beta of 1.34.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Canaccord Genuity Group dropped their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Citigroup cut their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a report on Wednesday, January 8th. Stephens lifted their price target on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada cut their price objective on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.20.

Insider Buying and Selling at Health Catalyst

In other news, insider Linda Llewelyn sold 6,441 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total transaction of $34,974.63. Following the completion of the transaction, the insider now directly owns 85,819 shares in the company, valued at approximately $465,997.17. This represents a 6.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total transaction of $67,050.00. Following the transaction, the insider now owns 236,950 shares in the company, valued at $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 87,610 shares of company stock valued at $664,043 over the last three months. 2.50% of the stock is owned by company insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.